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KEYWORDS	
	 A	micellar	 liquid	chromatographic	method	was	developed	 for	determination	of	 tinidazole	 in
bulk,	dosage	forms	and	human	plasma	using	intersil	cyano	column	and	a	mobile	phase	of	0.1
M	sodium	dodecyl	sulphate,	20%	1‐propanol,	0.3%	triethylamine	in	0.02	M	orthophosphoric
acid:water	 (60:40,	 v:v)	 (pH	 =	 4).	 The	 U.V.	 detection	 was	 achieved	 at	 311	 nm.	 Various
chromatographic	 parameters	 were	 investigated	 to	 select	 the	 optimum	 conditions	 for	 the
separation,	 e.g.	 types	 of	 columns,	 pH	 of	 mobile	 phase,	 concentration	 of	 sodium	 dodecyl
sulphate,	1‐propanol,	triethylamine,	etc.	The	method	was	linear	over	the	concentration	range
40‐200	µg/mL	with	regression	coefficient	0.999.	The	result	obtained	by	the	proposed	method
was	 compared	 with	 that	 obtained	 by	 the	 reference	 HPLC	 technique.	 Furthermore,	 the
proposed	method	was	successfully	applied	as	stability‐indicating	method	for	determination	of
tinidazole	 under	 different	 stressed	 conditions.	 The	 method	 showed	 good	 selectivity,
repeatability,	 linearity	 and	 sensitivity	 according	 to	 the	 evaluation	 of	 the	 validation
parameters.	
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1.	Introduction	
	
Tinidazole	 (TIN),	 is	 a	 5‐nitroimidazole	 compound	 with	
selective	activity	against	anaerobic	bacteria	and	protozoa.	TIN	
has	no	activity	against	aerobic	bacteria	so,	it	must	be	combined	
with	 other	 antibacterial	 agents	 in	 the	 treatment	 of	 mixed	
infections	 involving	 aerobic	 and	 anaerobic	 bacteria.	 TIN	 has	
also	been	used	successfully	alone	or	in	combination	with	other	
antimicrobial	 agents	 for	 prophylaxis	 in	 patients	 undergoing	
elective	 colonic	 and	 abdominal	 surgery,	 emergency	 appen‐
dectomy	 and	 gynecological	 surgery	 [1].	 It	 is	 chemically	
described	 as	 1‐[2‐(ethylsulphonyl)	 ethyl]‐2‐methyl‐5‐nitro‐1H	
‐imidazole	 [2]	 (M.W.	 =	 247.3	 g,	 pKa	 =	 0)	 (Figure	 1).	 TIN	 bulk	
drug	 is	 official	 in	 British	 pharmacopeia	 [3],	 United	 State	
Pharmacopeia	[4]	and	European	Pharmacopeia	[5].	
Many	 methods	 for	 analysis	 of	 the	 cited	 compound	 have	
been	 reported,	 e.g.	 titrimetric	 method	 [3,5],	 spectrophoto‐
metric	methods	[6,7],	flow	injection	analysis	[8],	spectrofluori‐
metric	 method	 [9,10],	 electrochemical	 methods	 [11,12]	 and	
chromatographic	 methods	 [13‐16].	 No	 micellar	 liquid	 chro‐
mategraphic	method	for	simultaneous	determination	of	TIN	is	
available	in	the	literature	
Micellar	liquid	chromatography	(MLC)	is	a	form	of	reversed	
phase	 liquid	 chromatography	 that	 uses	 an	 aqueous	 micellar	
solution	as	the	mobile	phase.	This	technique	is	used	mainly	to	
enhance	retention	and	selectivity	of	various	solutes	that	would	
otherwise	be	inseparable	or	poorly	resolved.	
	
	
	
Figure	 1. Structure	 of	 TIN,	 1‐(2‐ethylsulfonylethyl)‐2‐methyl‐5‐nitro‐
imidazole.	
	
One	of	the	most	advantageous	is	the	ability	to	directly	inject	
physiological	 fluids.	 Micelles	 have	 an	 ability	 to	 solubilize	
proteins	which	enables	MLC	to	be	useful	in	analyzing	untreated	
biological	 fluids	 such	 as	 plasma,	 serum,	 and	 urine.	 MLC	 is	 a	
better	 choice	 than	 ion‐exchange	 LC	 or	 ion‐pairing	 LC	 for	
separation	of	 charged	molecules	 and	mixtures	of	 charged	and	
neutral	species.	Another	novel	application	of	MLC	involves	the	
440	 Rizk	et	al.	/	European	Journal	of	Chemistry	5	(3)	(2014)	439‐445	
	
separation	and	analysis	of	inorganic	compounds,	mostly	simple	
ions.	This	is	a	relatively	new	area	for	MLC	[17‐19].	
The	aim	of	this	work	is	to	perform	more	accurate,	reliable,	
fast	and	validated	MLC	method	for	determination	of	TIN	alone	
or	 in	 combination	 with	 ciprofloxacin	 or	 norfloxacin	 in	 bulk,	
dosage	form	and	spiked	human	plasma	with	a	simple	and	rapid	
sample	 preparation	 especially	 for	 the	 routine	 analysis.	
Different	 chromatographic	 parameters	 were	 investigated	 to	
select	the	optimum	conditions	for	the	separation	and	applying	
as	 stability‐indicating	method	 for	 determination	 of	 TIN	under	
different	stress	conditions.	The	result	obtained	by	the	proposed	
method	 was	 compared	 with	 that	 obtained	 by	 the	 HPLC	
technique	 [20].	 The	 method	 was	 validated	 according	 to	 the	
international	 conference	 on	 harmonization	 guidelines	 (ICH)	
[21].	
	
2.	Experimental	
	
2.1.	Materials	
	
TIN	 (99.5%)	 was	 kindly	 supplied	 by	 Multiapex	 Pharma	
Drug	Company	(Badr	City,	Egypt).	Ciprofloxacin	(CIP)	(99.8%)	
was	kindly	supplied	by	Memphis	Drug	Company	(Cairo,	Egypt).	
Norfloxacin	 (NOR)	 (99.9%)	 was	 kindly	 supplied	 by	 Memphis	
Drug	 Company	 (Cairo,	 Egypt).	 The	 pharmaceutical	 products	
used	were	Ciprogyl	tablets	(under	trial)	labelled	to	contain	600	
mg	 TIN/tab,	 500	 mg	 CIP	 /tab,	 were	 obtained	 from	 Research	
and	Development	Section	 in	Memphis	Company,	Egypt.	Conaz	
tablets	 (Batch	 9160034)	 (Pharonia	 Pharmaceutical	 Company,	
Egypt)	 and	 Norfloxacin‐TZ	 tablets	 (Batch	 02321)	 (Sigma	
Pharmaceutical	 Company,	 Egypt)	 were	 purchased	 from	 the	
local	 pharmacy.	 They	 contain	 600	mg	 TIN	 and	 400	mg	NOR/	
tab.	 Plasma	 samples	 were	 obtained	 from	 Egyptian	 Research	
and	 Development	 Company	 and	 kept	 frozen	 until	 using	 after	
gentle	thawing.	
	
2.2.	Reagents	and	chemicals	
	
All	Reagents	were	of	analytical	reagent	grade	and	solvents	
were	 of	HPLC	 grade.	 High	 purity	water	was	 obtained	 by	 Elga	
Labwater,	Prima	7	(UK)	and	it	was	used	throughout	the	study.	
Methanol,	 1‐propanol	 and	 acetonitrile	 (HPLC	 grade)	 were	
obtained	 from	 Sigma‐Aldrich	 (Germany).	 Ortho‐phosphoric	
acid	 (85%),	 triethylamine	(TEA)	and	sodium	dodecyl	sulphate	
(SDS,	 99%)	 were	 obtained	 from	 Riedel‐deHäen	 (Sleeze,	
Germany).	 Sodium	 hydroxide	 and	 hydrochloric	 acid	 (32%)	
were	 purchased	 from	 El‐Nasr	 Company,	 Egypt.	 Hydrogen	
peroxide	 (30%)	was	obtained	 from	Luna	 industrial	 group	 (6th	
of	October	City,	Egypt).		
	
2.3.	Instrumentations		
	
The	MLC	method	was	performed	on	Agilent1200	HPLC	auto	
sampler	 system	 equipped	 with	 UV	 detector	 1200	 (Germany)	
and	HPLC	quaternary	pump	1200	(Germany).	Analytical	data	is	
stored	 in	 a	 computer	 equipped	with	 Agilent	 software.	 Vortex	
used	 was	 VWR	 VV3	 S540	 International	 (West	 Charter,	 USA).	
Centrifuge	used	was	centurion,	(West	Sussex,	UK).	The	pH	was	
measured	with	Jenway	pH	meter,	3510,	(Essex,	UK).	The	mobile	
phase	 was	 filtered	 through	 Charles	 Austen	 pumps	 Ltd	 filter,	
model‐B100	 SE	 (England,	 UK).	 Ultrasonic	 bath	 used	 was	
Falc.,	(Treviglio,	 Italy).	 The	 mobile	 phase	 and	 the	 injected	
solutions	were	 filtered	 through	 0.45	μm	 pore	 filters	 (Gelman,	
Germany).	
		
2.4.	Chromatographic	conditions	
	
MLC	 was	 performed	 on	 an	 intersil	 cyano	 column	 (5	 µm	
particle	 size,	 25	 cm	 ×	 150	mm	 i.d.),	 (GL	 Sciences	 Inc.,	 Japan)	
using	micellar	 mobile	 phase	 consisting	 of	 0.1	M	 SDS,	 20%	 1‐
propanol,	 0.3%	 TEA	 in	 0.02	 M	 ortho‐phosphoric	 acid:	 water	
(60:40,	 v:v)	 (pH	 =	 4).	 The	 mobile	 phase	 was	 filtered	 and	
sonicated	for	30	min	before	use.	The	flow	rate	was	1.0	mL/min	
and	sample	injection	volumes	were	20	μL	at	room	temperature	
(25	°C).	The	UV	detector	was	operated	at	311	nm.		
	
2.5.	Standard	solutions	
	
Standard	stock	solutions	of	TIN	/	CIP	combination	(500	µg	
TIN	and	416.7	µg	CIP/mL)	and	TIN	/	NOR	combination	(500	µg	
TIN	and	333.33	µg	NOR/mL	were	prepared	by	dissolving	50	mg	
of	TIN	and	41.67	mg	CIP	or	33.33	mg	NOR	in	100	mL	methanol	
then	 the	 solution	 was	 sonicated	 in	 an	 ultrasonic	 bath	 for	 5	
minutes.	 The	 solutions	were	 found	 to	 be	 stable	 for	 3	 days	 at	
room	temperature.	
Working	standard	solutions	(40‐200	µg/mL)	TIN	combined	
with	 CIP	 or	 NOR	 were	 prepared	 by	 serial	 dilution	 of	 the	
standard	solution	with	the	mobile	phase.	
	
2.6.	Preparation	of	pharmaceutical	products	
	
Take	the	contents	of	20	tablets	and	determine	the	average	
weight	 of	 content	 per	 tablet.	 Accurate	 weight	 of	 the	 powder	
equivalent	 to	 50	 mg	 ITC	 was	 dissolved	 in	 100	 mL	 methanol	
then	sonication	for	15	min	and	filtered.	
	
2.7.	Plasma	sample	extraction	
	
1	 mL	 of	 human	 plasma	was	 transferred	 into	 a	 centrifuge	
tube,	 spiked	 with	 1	 mL	 of	 TIN	 and	 deprotenized	 with	 2	 mL	
acetonitrile	 (ACN),	 then	 vortex.	 Final	 concentrations	were	 80,	
100	 and	 120	 μg	 TIN/mL,	 respectively.	 The	 solutions	 were	
centrifuged	 at	 5000	 rpm	 for	 15	 minutes.	 Then,	 the	 solutions	
were	 filtered	 through	 a	 disposable	 syringe	 filter	 (0.45	 μm)	
before	column	injection.	
	
2.8.	Sample	degradation	
	
An	 appropriate	 amount	 of	 TIN	 powder	 at	 a	 final	
concentration	of	500	μg/mL	in	1	N	alcoholic	HCl	was	left	for	24	
hrs	then	the	solution	was	filtered	and	2	mL	was	taken	into	10	
mL	 volumetric	 flask	 and	 the	 volume	was	 completed	with	 the	
mobile	 phase	 and	 triplicate	 20	 μL	 injections	were	made.	 The	
same	experiment	was	repeated	but	in	1	N	alcoholic	NaOH,	30%	
H2O2.	
Each	 experiment	 was	 carried	 out	 in	 triplicate	 and	 all	
solutions	were	 injected	 in	 triplicate.	 The	 nominal	 contents	 of	
each	 one	 were	 calculated	 using	 the	 constructed	 calibration	
graph	or	from	the	corresponding	regression	equation.	
	
3.	Results	and	discussion	
	
The	proposed	MLC	method	represents	a	rapid	and	sensitive	
stability‐indicating	 method	 for	 the	 separation	 and	 simulta‐
neous	determination	of	TIN	 in	combination	with	either	CIP	or	
NOR	in	bulk	and	commercial	tablets.	Moreover,	it	was	extended	
to	 investigate	 the	 inherent	 stability	 of	 TIN	 under	 different	
stress	conditions.	By	virtue	of	its	high	sensitivity,	the	proposed	
method	 was	 applied	 for	 the	 determination	 of	 TIN	 in	 human	
plasma	with	no	need	for	tedious	sample	pre‐treatment	steps.	
Different	 parameters	 affecting	 the	 chromatographic	
performance	of	TIN	were	carefully	studied	in	order	to	achieve	
the	most	suitable	chromatographic	system.	
	
3.1.	Choice	of	appropriate	detection	wavelength	
	
The	 absorption	 spectrum	 of	 TIN	 in	 the	 mobile	 phase	
exhibits	 maximum	 absorption	 at	 311	 nm	 which	 allows	 also	
determination	of	CIP	and	NOR	at	 this	wavelength.	So,	311	nm	
was	 selected	 as	 the	 optimum	 detection	 wavelength	 for	
detection	and	selective	determination	of	TIN	with	a	reasonable	
sensitivity	in	the	presence	of	CIP	or	NOR.		
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Table	1.	Performance	data	of	the	proposed	method	for	determination	of	TIN/CIP	and	TIN/NOR	in	pure	form.	
Parameter	 Results	
TIN/CIP TIN/NOR	
Concentration	range	(µg/mL)	 40‐200	 40‐200	
LOD	(µg/mL)	 5.6	 4.07	
LOQ	(µg/mL)	 17.1 12.34	
r	 0.999 0.999	
%RSD	 1.9 1.2	
%	Error	(%	RSD/√n)	 0.4 0.25	
	
	
	(a)	
	(b)	
	
Figure	2.	Representative	chromatogram	using	the	proposed	method	for	simultaneous	determination	of	TIN	(100	µg/mL)	in	the	presence	of	CIP	(a),	TIN	(100	
µg/mL)	in	the	presence	of	NOR	(b).	
	
	
3.2.	Choice	of	column	
	
To	investigate	the	chromatographic	performance,	different	
columns	 had	 been	 tried,	 these	 include	 reversed‐phase	 C8,	
reversed‐phase	 C18,	 two	 bonded	 phase	 cyano	 and	 bonded	
phase	 phenyl	 columns.	 Experimental	 trials	 revealed	 that	 the	
Intersil	 cyano	 column	 (5	 µm	 particle	 size,	 25	 cm	 length,	 150	
mm	 i.d,	 GL	 Sciences	 Inc.,	 Japan)	 was	 the	 most	 suitable	 one	
giving	 narrower	 symmetric	 peaks	 and	 highest	 number	 of	
theoretical	plates	within	a	reasonable	analysis	time.		
	
3.3.	Mobile	phase	composition	
	
To	achieve	the	best	chromatographic	conditions,	the	mobile	
phase	 composition	 was	 optimized	 to	 provide	 sufficient	
selectivity	 and	 sensitivity	 in	 a	 short	 separation	 time.	 The	
studied	 variables	 included;	 the	 pH	 of	 the	 mobile	 phase,	 flow	
rate,	concentration	of	SDS,	organic	modifier	and	TEA.		
	
3.3.1.	pH	of	the	mobile	phase	
	
In	order	to	select	the	optimum	pH	value	for	the	analysis	of	
TIN,	the	pH	of	the	mobile	phase	was	studied	over	the	range	of	
2.5‐4.5.	 Mobile	 phases	 with	 pH	 values	 ranged	 from	 3.5‐4.0	
provided	 suitable	 peak	 symmetry	 and	 better	 peak	 shape.	
Increasing	 the	 pH	 of	 the	mobile	 phase	more	 than	 4.0	 caused	
increase	 in	 the	 retention	 time	 of	 TIN.	 Finally,	 pH	 =	 4.0	 was	
selected	as	the	optimum	pH	value	for	the	mobile	phase	in	this	
study	yielding	highest	number	of	 theoretical	plates	with	good	
peak	shape	and	lowest	peak	tailing.	
	
3.3.2.	Flow	rate	of	the	mobile	phase	
	
The	effect	of	flow	rate	of	the	mobile	phase	on	the	retention	
of	TIN	was	investigated	over	the	range	of	1.0‐2.0	mL/min.	Flow	
rate	 of	 1.0	mL/min	was	 chosen	 since	 it	 provides	 better	 peak	
shape	 and	 better	 resolution	 within	 a	 reasonable	 time.	 After	
optimization	 of	 these	 variables,	 best	 peak	 shape,	 lowest	 peak	
tailing	 was	 achieved	 with	 well‐defined	 peaks	 and	 good	
sensitivity	 within	 a	 reasonable	 analytical	 run	 time.	 Figure	 2	
represents	 a	 chromatogram	 indicating	 the	 good	 retention	 of	
TIN	under	the	optimum	chromatographic	conditions.	
	
3.4.	Method	validation	
	
The	 validity	 of	 the	 proposed	 method	 was	 assessed	 by	
studying	 the	 following	 parameters	 in	 accordance	 to	 ICH	
guideline	 [21]:	 linearity,	 range,	 LOD,	LOQ,	 accuracy,	precision,	
selectivity,	 sample	 solution	 stability,	 mobile	 phase	 stability,	
system	suitability	and	robustness.	
	
3.4.1.	Linearity	and	range	
	
Under	 the	 optimum	 chromatographic	 conditions,	 a	 linear	
relationship	 was	 established	 by	 plotting	 average	 peak	 areas	
against	TIN	concentrations	(µg/mL)	as	shown	in	Figure	3.	The	
calibration	 graphs	 were	 found	 to	 be	 rectilinear	 over	 the	
concentration	ranges	of	40‐200	(µg/	mL)	TIN.	
Statistical	 analysis	 of	 the	 data	 showed	 good	 correlation	
coefficients	(r)	and	relative	standard	deviation	as	mentioned	in	
Table	1.	
	
y	=	39.39x	+	134.4	(r	=	0.999)	for	TIN/CIP	 	 (1)	
	
y	=	41.24x	+	3.599	(r	=	0.999)	for	TIN/NOR	 	 (2)	
	
Limit	of	detection	 (LOD)	 and	 limit	of	quantification	 (LOQ)	
for	 TIN	 were	 calculated	 according	 to	 ICH	 Q2	 (R1)	
recommendation	[21]	and	the	results	are	shown	in	Table	1.		
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Table	2.	Application	of	the	proposed	MLC	method	for	the	determination	of	TIN	in	combination	with	CIP.	
Parameter	 Proposed	method		 Comparison	method	[20]
Conc.	taken	(µg/mL)	 Conc.	found	(µg/mL) %	Found	* %	Found*	
40	 39.20 98.0 99.2	
60	 61.4	 102.3	 101.5	
80	 80.7 100.9 102.1	
100	 98.0 98.0 98.5	
120	 122.5	 102.1	 103.8	
200	 199.9 100.0 101.3	
x±SD	 100.2±1.9	 101.1±1.9	
t	 0.8	(1.8)	**	
F	 1.0	(5.1)	**	
*	Each	result	is	the	average	of	three	separate	determinations.		
**	Values	between	parentheses	are	the	tabulated	t	and	F	values	at	p	=	0.05	[22].	
	
	
Table	3.	Application	of	the	proposed	MLC	method	for	the	determination	of	TIN	in	combination	with	NOR.	
Parameter	 Proposed	method	 Comparison	method	[20]
Conc.	taken	(µg/mL)	 Conc.	found	(µg/mL) %	Found	* %	Found	
40	 40.7	 101.8	 100.5	
60	 60.8 101.3 100.9	
80	 79.7 99.6 101.2	
100	 100.3 100.3 99.4	
120	 118.3 98.6 97.9	
140	 142.2	 101.6	 100.5	
200	 200.2 100.1 99.2	
x±SD	 100.5±1.2	 99.9±1.2	
t	 0.8	(1.8)	**	
F	 1.0	(3.8)	**	
*	Each	result	is	the	average	of	three	separate	determinations.		
**	Values	between	parentheses	are	the	tabulated	t	and	F	values	at	p	=	0.05	[22].	
	
	
	
	(a)	
	
(b)	
	
Figure	3.	Calibration	curve	for	simultaneous	determination	of	TIN	in	pure	form	using	the	proposed	MLC	method	in	presence	of	(A)	CIP	in	pure	form,	(B)	NOR	in	
pure	form.	
	
	
3.4.2.	Accuracy	
	
To	prove	the	accuracy	of	the	proposed	method,	the	results	
of	the	assay	of	TIN	in	pure	form	by	the	proposed	MLC	method	
were	compared	with	those	obtained	using	a	comparison	HPLC	
method	[20].	Statistical	 comparison	of	 the	results	obtained	by	
the	 proposed	 MLC	 method	 with	 those	 obtained	 by	 the	
comparison	 method	 using	 t‐test	 and	 F‐test	 revealed	 no	
significant	 differences	 between	 the	 performance	 of	 the	 two	
methods	 regarding	 the	 accuracy	 and	 precision,	 respectively.	
The	results	are	shown	in	Table	2	and	3.	
The	comparison	HPLC	method	involved	the	use	of	a	mobile	
phase	consisting	of	0.05	M	SDS:	6%	propan‐1‐ol	(47:3,	v:v)	and	
µbondapack	cyano	column	at	320	nm	[20].	
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Table	4.	Precision	data	of	the	proposed	method	for	the	determination	of	TIN	in	dosage	forms.	
%	Found±SD	 %RSD	 %Error	
Intra‐day	precision	
Ciprogyl	tab	 108.0±1.0 0.9 0.3	
Conaz	tab	 94.3±0.6 0.6 0.2	
Norfloxacin‐TZ	tab	 104.4±0.7 0.7 0.2	
Inter‐day	precision	
Ciprogyl	tab	 107.0±2.4 2.2 0.5	
Conaz	tab	 95.7±2.2 2.3 0.5	
Norfloxacin‐TZ	tab	 102.2±2.6 2.5 0.6	
	
	
Table	5.	System	suitability	test	parameters	for	the	developed	MLC	method	for	TIN.	
Parameter	 TIN/CIP	 TIN/NOR	
No	of	theoretical	plates,	N	 7145 4859	
Capacity	Factor,	K’	 0.84 0.84	
Selectivity	factor,	α	 1.95 1.92	
Resolution	factor,	Rs	 8.2	 5.51	
	
	
Table	6.	Application	of	the	proposed	and	comparison	method	to	determination	of	TIN	in	tablets.	
Pharmaceutical	preparation	 %	Found *,	mean±SD	
Proposed	 Reference	[20]	
Ciprogyl	tab	 105.8±1.6 105.2±1.7	
t	**	 0.5 ‐	
F	**	 1.8 ‐	
Conaz	tab	 97.3±1.7 97.8±1.7	
t	**	 0.6	 ‐	
F	**	 1.1 ‐	
Norfloxacin‐TZ	tab	 101.4±1.3	 101.3±1.5	
t	**	 0.4	 ‐	
F	**	 2.1	 ‐	
*	Each	result	is	the	average	of	four	separate	determinations	and	each	one	repeated	three	times.		
**	The	tabulated	t	=	1.9	and	F	=	9.3	at	n	=	12	and	p	=	0.05	[22].	
	
	
3.4.3.	Precision	
	
Intra‐day	precision	of	 the	proposed	method	was	 achieved	
by	six	replicate	determinations	of	100	µg/mL	TIN	in	the	three	
dosage	forms	on	three	successive	times	in	the	same	day.	Inter‐
day	 precision	 was	 performed	 as	 intra‐day	 but	 on	 three	
successive	days.	Small	values	of	%error	and	%RSD	revealed	the	
precision	of	the	proposed	method.	The	results	are	illustrated	in	
Table	4.	
	
3.4.4.	Selectivity	
	
The	 specificity	 of	 the	 proposed	 MLC	 method	 was	
established	 by	 its	 ability	 to	 determine	 TIN	 in	 commercial	
tablets	 without	 interference	 from	 other	 drugs	 or	 common	
tablet	excipients.	Neither	the	combined	drugs	nor	the	common	
tablet	 excipients	 show	 any	 interfering	 peaks	 at	 the	 retention	
times	of	the	drug,	which	proved	the	homogeneity	and	purity	of	
the	peak.	Furthermore,	to	evaluate	the	specificity	of	the	method	
to	determine	TIN	 in	human	plasma,	blank	plasma	was	diluted	
with	 the	 micellar	 mobile	 phase	 and	 injected	 under	 the	
recommended	 chromatographic	 conditions.	 No	 endogenous	
interference	was	observed	at	the	retention	time	of	TIN,	proving	
the	specificity	of	the	method.	
Forced	 Degradation	 studies	 were	 also	 performed	 to	
evaluate	 the	 validity	 of	 the	 method.	 The	 results	 obtained	
indicated	 that	 the	proposed	MLC	method	 is	selective	and	able	
to	determine	TIN	in	presence	of	its	degradation	products.	
	
3.4.5.	Sample	solution	stability	and	mobile	phase	stability	
	
Evaluation	of	the	stability	of	TIN	 in	 its	 three	dosage	forms	
solution	 was	 achieved	 by	 quantification	 of	 TIN	 on	 three	
successive	 days	 and	 comparison	 to	 freshly	 prepared	 dosage	
forms	solution.	Similarly,	the	stability	of	the	mobile	phase	was	
checked.	No	significant	changes	were	observed,	proved	that	the	
sample	solution	and	mobile	phase	used	during	the	assay	were	
stable	up	to	3	days.	
	
	
3.4.6.	System	suitability	test	(SST)	
	
Evaluation	 of	 SST	 parameters	 was	 performed	 during	 the	
development	 and	 optimization	 of	 the	 method.	 The	 test	 was	
performed	 by	 injecting	 the	 standard	 sample	 in	 triplicate	 and	
the	 parameters	 were	 calculated	 as	 reported	 by	 USP	 [4].	 SST	
parameters	 include	 capacity	 factor	 (k’),	 selectivity	 factor	 (α),	
resolution	factor	(Rs),	column	efficiency	(Number	of	theoretical	
plates,	 N).	 The	 final	 SST	 parameters	 under	 the	 optimum	
chromatographic	conditions	are	illustrated	in	Table	5.	
	
3.4.7.	Robustness	
	
To	 assess	 the	 robustness	 of	 the	 proposed	 MLC	 method,	
chromatographic	 conditions	 were	 deliberately	 altered.	 The	
tested	 variables	 included;	 concentration	 of	 1‐propanol	
(20%±0.5,	v:v),	 strength	of	ortho‐phosphoric	acid	 (0.02±0.005	
M),	 concentration	 of	 TEA	 (0.3±0.01%).	 The	 efficiency	 of	 the	
separation	 of	 TIN	 was	 not	 affected	 by	 all	 the	 varied	
chromatographic	 conditions	 indicating	 the	 reliability	 of	 the	
proposed	method.	
	
3.5.	Applications	
	
3.5.1.	Application	of	the	proposed	method	to	the	
determination	of	TIN	in	tablets	
	
The	 developed	 MLC	 method	 was	 applied	 successfully	 for	
the	 assay	 of	 TIN	 in	 commercial	 tablets	 either	 in	 combination	
with	 NOR	 or	 CIP.	 No	 interferences	 were	 encountered	 from	
common	tablet	excipients.	
The	 results	 obtained	 by	 the	 developed	MLC	method	were	
statistically	 compared	 with	 those	 of	 the	 comparison	 HPLC	
method	[20]	using	t‐test	and	F‐test.	In	both	tests,	the	calculated	
values	 did	 not	 exceed	 the	 theoretical	 values	 at	 the	 95%	
confidence	level,	which	indicated	that	there	were	no	significant	
differences	 between	 the	 developed	 and	 comparison	 methods	
regarding	accuracy	and	precision,	respectively.	The	results	are	
shown	in	Table	6.		
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Table	7.	Assay	results	for	the	determination	of	TIN	in	spiked	human	plasma	using	the	proposed	method.	
Parameter	 Conc.	added	(µg/mL)	 Conc.	found	(µg/mL)	 %	Recovery	*	
Spiked	plasma	 80	 80.9 101.1	
100	 105.2 105.2	
120	 121.1 103.9	
Mean%±SD	 103.4±2.1	
%R.S.D	 2.0	
%	Error	 0.7	
*	Each	result	is	the	average	of	three	separate	determinations.	
	
	
	(a)	
	(b)	
	
Figure	4.	Representative	chromatograms	showing	(a)	Blank	plasma	and	(b)	plasma	sample	spiked	with	120	µg/mL	TIN.	
	
	
3.5.2.	Application	of	the	proposed	method	to	the	
determination	of	TIN	in	spiked	human	plasma	
	
MLC	allows	biological	samples	to	be	analysed	without	prior	
tedious	 pre‐treatment	 for	 plasma	 protein	 precipitation	 or	
elimination	 of	 other	 interfering	 substances,	 thus	 considerably	
reducing	the	cost	and	analysis	time.	The	proposed	MLC	method	
was	successfully	applied	to	the	determination	of	TIN	in	spiked	
human	plasma.	
The	 proposed	 method	 showed	 satisfactory	 results	 for	
determination	 of	 TIN	 in	 spiked	 human	 plasma.	 The	 assay	
results	using	the	proposed	method	are	summarized	in	Table	7.	
Figure	 4	 shows	 representative	 chromatograms	 for	 blank	 and	
spiked	plasma	samples.	
	
3.5.3.	Results	of	stress	testing	studies	
	
The	 proposed	method	was	 applied	 to	 assess	 the	 inherent	
stability	of	TIN	under	different	conditions	like:	alkaline,	acidic,	
oxidative	 and	photolytic	 conditions.	 The	 studied	 compound	 is	
found	 to	 be	 highly	 labile	 to	 alkaline	 hydrolysis,	 the	 solution	
upon	 addition	 of	NaOH,	 acquires	 a	 yellow	 colour	 [23].	Where	
the	 acidic	 degradation	 using	 1	 N	 HCl	 for	 24	 hrs	 resulted	 in	
about	 2%.	 Exposure	 of	 TIN	 to	 oxidative	 degradation	 by	 30%	
H2O2	for	24	hrs,	about	62.5%	degradation	of	TIN	was	observed.		
	
4.	Conclusions	
	
The	 proposed	 MLC	 method	 represents	 a	 new	 rapid	 and	
sensitive	 stability‐indicating	 assay	 for	 the	 separation	 and	
simultaneous	determination	of	TIN	in	bulk	and	pharmaceutical	
dosage	 form	 containing	 TIN/CIP	 or	 TIN/NOR.	 The	 proposed	
method	 was	 applied	 for	 the	 determination	 of	 TIN	 in	 human	
plasma	with	no	need	for	tedious	sample	pre‐treatment	steps.	In	
addition,	the	proposed	method	was	extended	to	investigate	the	
inherent	stability	of	TIN	under	different	stress	conditions.	 	
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